Ketamine Clinics Los Angeles (KCLA) Announces Free, Informative Webinar to Address Misconceptions Surrounding the Death of Actor Matthew Perry
Due to the media storm surrounding the recently announced cause of death for late actor Matthew Perry and his reported use of ketamine at the time of his death, leading mental health…
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital
Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the company has signed and fully drawn a term loan of 92 million Euros with funds managed by Athyrium Capital Management, LP…
Menarini India strengthens its Dermatology portfolio. Enters into an exclusive partnership agreement with Pierre Fabre Laboratories to market Global brands Eau Thermale Avene and Ducray in India
A. Menarini India Private Limited (‘Menarini India’), a leading Italian pharmaceutical company strengthens its presence in dermatology, and has solidified its strategic position by entering into an exclusive partnership with…
Signia Marks a New Era with the Inauguration of its 350th BestSound Center in Partnership with HearSens Hearing Clinic in Hyderabad
Signia, a distinguished brand within the WS Audiology group and a leader in hearing aid innovation, celebrates a significant milestone with the launch of its 350th BestSound Center in Hyderabad.…
NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it has signed a License Data and Technical Information Agreement with Columbia University for rights to data…
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca’s WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis…
Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT® (amivantamab-vmjw) Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) together with a New Drug Application (NDA) seeking…
Navamedic ASA: Renewed contract signed with Vitaflo International Limited
Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces it has renewed its contract with Vitaflo International Limited (Vitaflo International),…
On/go for\Good provides the main donation to open a mental health center for children in war-torn Ukraine
On/go for\Good, a charitable foundation founded by Intrivo co-founders, is delighted to announce the opening of a much-needed mental health facility for children in war-torn Ukraine. In partnership with local philanthropic partners, On/go for\Good…
Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’), an innovative clinical stage company, announced that it has dosed the first patient with Rheumatoid Arthritis (RA) in a Phase…
